Skip to main content

Table 2 Implant characteristics, patient distribution, and ambulatory follow-up care

From: Detection of arrhythmia using an implantable cardiac monitor following a cryptogenic stroke: a single-center observational study

Parameter

Overall population (n = 88)

Implant manufacturer, n (%)

 Biotronik

58 (65.9)

 Medtronic

17 (19.3)

 St. Jude

13 (14.8)

Implant designation, n (%)

 Biomonitor2-AF

58 (65.9)

 Reveal LINQ

2 (2.3)

 Reveal XT

15 (17.0)

 SJM confirm

13 (14.8)

Tele-monitoring, n (%)

 On

58 (65.9)

 Off

30 (34.1)

Ambulatory follow-up care, n (%)

 Rostock University Medical Center

58 (65.9)

 Doctor’s office

30 (34.1)

 Observation period (months), median (range)

21.5 (1–33)